Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Treasury Shares (2021 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Treasury Shares for 4 consecutive years, with $145000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Treasury Shares fell 54.26% to $145000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $145000.0, a 54.26% decrease, with the full-year FY2023 number at $361500.0, up 12.01% from a year prior.
  • Treasury Shares was $145000.0 for Q3 2024 at Werewolf Therapeutics, down from $150000.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $498000.0 in Q1 2021 to a low of $126000.0 in Q3 2022.
  • A 4-year average of $298694.6 and a median of $319862.5 in 2022 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: tumbled 64.61% in 2022, then surged 151.59% in 2023.
  • Werewolf Therapeutics' Treasury Shares stood at $356000.0 in 2021, then decreased by 9.35% to $322725.0 in 2022, then grew by 12.01% to $361500.0 in 2023, then tumbled by 59.89% to $145000.0 in 2024.
  • Per Business Quant, the three most recent readings for HOWL's Treasury Shares are $145000.0 (Q3 2024), $150000.0 (Q2 2024), and $361500.0 (Q1 2024).